Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Stopped early · Phase 2

Conditions studied: Head and Neck Cancer

In brief

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Key facts

Study ID

NCT00750555

Run by

Geisinger Clinic

People needed

4

Starts

2008-09-01

Expected to finish

2009-12-01

Last updated by the study team

2019-02-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage III, IV SCCHN
• Completed curative treatment

You may not qualify if…

• Prior chemotherapy or radiotherapy
• Recurrent disease

Where it is running

• Geisinger Health System — Danville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.